Categories

Chemistry

3D Printing, Surface technologies and New Materials
- 3D Printing/Lithography Technologies
- Surface Technologies
Agriculture
- Agritec
Bio-based Economy, Food and Personal Care
- Composite Materials & New Materials
- Food, Nutrition & Personal Care
- Industrial Biotech
Digital Chemistry
- R&D Processes & Logistics
- Sensors and Measurement Techniques
- Simulations and Quantum Chemistry
- Sustainability
Energy, Cleantech and Environment
- Energy Generation / Storage
- Recycling
- Water & Mining

Digital Tech

Applications
- 3D-Print
- Blockchain
- e-Commerce
- Health & Lifestyle
- Jobs
- Mobility
- PropTech/ConTech/LegalTech
- Publishing
- Travel
FinTech
Tech/Infrastructure
- AdTech
- AI
- Big Data Analytics
- Business Analytics
- Cloud Infrastructure
- Communication
- Developer Tools
- IT Security
- Marketing
- Productivity-Tools
- Retail Intelligence
- Search
- Social
- Sustainability

Industrial Technology

Access
Applications
- Logistics
- Mobility
- Software
- Virtual and Augmented Reality
Illumination / Projection / Audio
Industrial Software
Metrology
Optical Metrology
Semiconductor
Tech/Infrastructure
- additive Manufacturing
- Energy Generation/Storage
- Energy Management
- Micro Systems Technology
- Production
- Quantum Technology
- Recycling
- Robotics
- Security/Access
- Sensornetworks

Life Sciences

Diagnostic
- Biosensors
- In-Vitro Dx
Digital Health
Green Biotech
Medical Technology
- Aesthetics
- cardiovascular devices
- Emergency Care
- Imaging & Navigation
- Neuromodulation
- New Materials
- Orthopedics/ 3-D-Printing
- Patient Monitoring
- Rehabilitation
Pharmaceuticals
- Animal Health
- Cardiology/Cardiovascular
- Drug Delivery
- Gene Therapy
- Hearing loss
- Immunology
- Infectious Diseases
- Metabolic Diseases
- Oncology
- Pain
- Regulatory
- Rejuvenation
R & D Tools

Tubulis

Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. Employing the company’s proprietary ADC development approach, Tubulis will advance a variety of conjugates, unlimited by indication

Press releases

HTGF Investment Tubulis

Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates Tubulis today announced the close of a €10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug…

Read